The global market for Specialty Generics is estimated at US$88.5 Billion in 2023 and is projected to reach US$173.1 Billion by 2030, growing at a CAGR of 10.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Specialty Generics Market]( "Specialty Generics Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Generic Injectables segment, which is expected to reach US$123.3 Billion by 2030 with a CAGR of 10.7%. The Other Types segment is also set to grow at 8.5% CAGR over the next 7 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $27.4 Billion in 2023, and China, forecasted to grow at an impressive 9.3% CAGR to reach $29.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Specialty Generics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Specialty Generics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Specialty Generics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Akorn Inc., Apotex Corp., Endo International plc., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 43 Featured):
- Akorn Inc.
- Apotex Corp.
- Endo International plc.
- Mallinckrodt
- Mylan N.V.
- Pfizer Inc.
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries
- Valeant Pharmaceuticals
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Specialty Generics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 2: World Historic Review for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 3: World 16-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 5: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 6: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 8: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 9: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 12: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 14: World Historic Review for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 15: World 16-Year Perspective for Inflammatory Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 17: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 18: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 20: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 21: World 16-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 25: World Specialty Generics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 27: USA Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 28: USA 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: USA Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: USA 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: Canada Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: Canada 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Canada Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Canada 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
JAPAN
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: Japan Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: Japan 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: Japan Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: Japan 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
CHINA
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 44: China Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 45: China Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: China 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 48: China Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: China 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
EUROPE
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: Europe 16-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: Europe 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
FRANCE
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 59: France Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: France Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: France 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: France Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: France 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
GERMANY
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: Germany Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: Germany 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Germany Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Germany 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: Italy Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: Italy 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: Italy Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: Italy 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: UK Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: UK 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: UK Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: UK 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Specialty Generics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
REST OF WORLD
- Table 95: Rest of World Recent Past, Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2014, 2024 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2014, 2024 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akorn Inc.
- Apotex Corp.
- Endo International plc.
- Mallinckrodt
- Mylan N.V.
- Pfizer Inc.
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries
- Valeant Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 94 |
| Published | May 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 88.5 Billion |
| Forecasted Market Value ( USD | $ 173.1 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
